IP Library › Granted Patent US 11,932,675
Granted Patent B2
US 11,932,675 · App. 17/067,508 · Granted Mar 19, 2024

PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved properties

Inventors: John Desjarlais (Pasadena, CA); Matthew Bernett (Pasadena, CA); Michael Hedvat (Pasadena, CA); Rajat Varma (Pasadena, CA); Suzanne Schubbert (Pasadena, CA); Christine Bonzon (Pasadena, CA); Rumana Rashid (Pasadena, CA); Juan Diaz (Pasadena, CA); Patrick Holder (South San Francisco, CA); Christine Huang (South San Francisco, CA)
Assignees: GENENTECH, INC.; XENCOR, INC.
C07K14/5443A61P35/00C07K16/2818A61K38/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,932,675
App. No.
17/067,508
Granted
Mar 19, 2024
Kind
B2
Abstract

The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.

Claims (15)

1. A composition comprising a variant IL-15 protein as compared to SEQ ID NO:2, said variant IL-15 protein comprising an amino acid modification selected from the group consisting of N71Q, N79Q, N112Q, S114del and S114A.

2. A pharmaceutical composition comprising the composition comprising a variant IL-15 protein according to claim 1 and a pharmaceutically acceptable carrier.

3. The composition according to claim 1 , wherein said variant IL-15 protein further comprises an amino acid modification selected from the group consisting of N1D, N4D, D8N, D30N, D61N, E64Q, N65D and Q108E.

4. The composition according to claim 1 , wherein said variant IL-15 protein comprises amino acid modifications selected from the group consisting of N71Q/N79Q, N71Q/N79Q/N112Q, N71Q/N79Q/S114del and N71Q/N79Q/S114A.

5. The composition according to claim 1 , wherein said variant IL 15 protein comprises amino acid modifications selected from the group consisting of N1D/N4D/D8N, N1D/N4D/N65D, N1D/D30N, N1D/D61N, N1D/D61N/E64Q/Q108E, N1D/E64Q, N1D/N65D, N1D/Q108E, N4D/D30N, N4D/D61N, N4D/D61N/N65D, N4D/D61N/E64Q/Q108E, N4D/E64Q, N4D/N65D, D8N/D61N, D8N/E64Q, D30N/E64Q, D30N/N65D, D30N/E64Q/N65D, D30N/Q180E, D61N/E64Q/N65D, E64Q/N65D, E64Q/Q108E and N65D/Q108E.

6. The composition according to claim 1 , wherein said variant IL 15 protein comprises the amino acid modifications N71Q/N79Q/N112Q.

7. The composition according to claim 1 , wherein said variant IL 15 protein comprises the amino acid modifications N71Q/N79Q/N112Q and D30N/N65D.

8. The composition according to claim 1 , wherein said variant IL-15 protein comprises the amino acid modifications N71Q/N79Q/N112Q and D30N/E64Q/N65D.

9. The pharmaceutical composition according to claim 2 , wherein said variant IL-15 protein further comprises an amino acid modification selected from the group consisting of N1D, N4D, D8N, D30N, D61N, E64Q, N65D and Q108E.

10. The pharmaceutical composition according to claim 2 , wherein said variant IL-15 protein comprises amino acid modifications selected from the group consisting of N71Q/N79Q, N71Q/N79Q/N112Q, N71Q/N79Q/S114del and N71Q/N79Q/S114A.

11. The pharmaceutical composition according to claim 2 , wherein said variant IL 15 protein comprises amino acid modifications selected from the group consisting of N1D/N4D/D8N, N1D/N4D/N65D, N1D/D30N, N1D/D61N, N1D/D61N/E64Q/Q108E, N1D/E64Q, N1D/N65D, N1D/Q108E, N4D/D30N, N4D/D61N, N4D/D61N/N65D, N4D/D61N/E64Q/Q108E, N4D/E64Q, N4D/N65D, D8N/D61N, D8N/E64Q, D30N/E64Q, D30N/N65D, D30N/E64Q/N65D, D30N/Q180E, D61N/E64Q/N65D, E64Q/N65D, E64Q/Q108E and N65D/Q108E.

12. The pharmaceutical composition according to claim 2 , wherein said variant IL 15 protein comprises the amino acid modifications N71Q/N79Q/N112Q.

13. The composition according to claim 2 , wherein said variant IL 15 protein comprises the amino acid modifications N71Q/N79Q/N112Q and D30N/N65D.

14. The composition according to claim 2 , wherein said variant IL-15 protein comprises the amino acid modifications N71Q/N79Q/N112Q and D30N/E64Q/N65D.

15. The composition according to claim 14 , wherein said variant IL-15 protein comprises the amino acid sequence of SEQ ID NO: 319.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2022
From: DESJARLAIS, JOHN; BERNETT, MATTHEW; HEDVAT, MICHAEL; VARMA, RAJAT; SCHUBBERT, SUZANNE; BONZON, CHRISTINE; RASHID, RUMANA; DIAZ, JUAN
To: XENCOR, INC.
Reel/Frame 059677/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2020
From: HOLDER, PATRICK; HUANG, CHRISTINE SHAOYU
To: GENENTECH, INC.
Reel/Frame 054150/0141 →
Continuity (4)
Provisional Application 63011208 · Apr 16, 2020
Provisional Application 62914265 · Oct 11, 2019
Provisional Application 62914317 · Oct 11, 2019
Related Publication 20210230243A1 · Jul 29, 2021